Skip to content
Prof. Dr. Mustafa Özdoğan · Medical Oncologist

Pregnancy Is Safe in Women with Early-Stage Breast Cancer and a BRCA Mutation

Pregnancy Is Safe in Women with Early-Stage Breast Cancer and a BRCA Mutation

In the Journal of Clinical Oncology, results from the largest study to date, published on 16 July 2020, show that pregnancy after breast cancer is safe in women with germline BRCA mutations.

The study findings provide reassuring evidence for women with germline (inherited) BRCA mutations and early-stage breast cancer that pregnancy after treatment is safe without worsening maternal health and is associated with favorable fetal (baby-related) outcomes. The findings are of great importance for professionals following young women with BRCA mutations and breast cancer, including medical oncologists and obstetricians.

Today, the age at first childbirth is rising because of the trend toward delaying childbearing, and increasing numbers of young women are therefore diagnosed with breast cancer before having children. Pregnancy is safe in women with a history of breast cancer and does not increase hormone-receptor-positive patients' risk of recurrence (cancer returning), even with such disease. However, information to counsel women with germline BRCA mutations on this subject remains very limited.

Approximately 12% of breast cancers occurring in women under 40 carry deleterious germline mutations in the BRCA1 and/or BRCA2 genes.

- Related topic: Who should undergo genetic testing for inherited breast cancer?

Study details and results

  • The authors studied women with germline BRCA mutations in an international, multicenter, hospital-based retrospective cohort (group) study to investigate the effect of pregnancy on breast cancer outcomes.
  • The study included women with deleterious germline BRCA mutations: 1252 women under 40 diagnosed with early-stage breast cancer between January 2000 and December 2012.
  • The primary endpoints were pregnancy rate and, between women with and without pregnancy after breast cancer, disease-free survival. Pregnancy outcomes and overall survival were secondary endpoints.
  • BRCA mutation distribution was as follows:
    • BRCA1 mutations in 811,
    • BRCA2 mutations in 430, and
    • both BRCA1 and BRCA2 mutations in 11 patients, among women with germline BRCA mutations totaling 1252 women.
  • Of these women, 195 had at least 1 pregnancy after breast cancer; the 10-year pregnancy rate was 19%.
  • Induced abortion and spontaneous miscarriage occurred in 16 women (8.2%) and 20 women (10.3%), respectively.
  • A total of 150 women gave birth to 170 babies.
  • Pregnancy complications occurred in 13 women (11.6%), and congenital anomalies in 2 (1.8%).
  • Median follow-up from breast cancer diagnosis was 8.3 years.
  • No difference in disease-free survival or overall survival was observed between pregnant and nonpregnant women (disease-free survival: HR 0.87; 95% CI, 0.61 to 1.23; p=0.41. Overall survival: HR 0.88; 95% CI, 0.50 to 1.56; p=0.66).

In conclusion, these findings provide reassuring evidence for women with a BRCA mutation that pregnancy after early-stage breast cancer does not put the mother at risk in terms of disease-free survival or overall survival.

Sources

Lambertini M, Ameye L, Hamy A-S, et al. Pregnancy After Breast Cancer in Patients With Germline BRCA Mutations. JCO; Published online 16 July 2020.

Appointment request

DROZDOGAN AI

Explore this article together

Ask about the article and read answers alongside published sources from our site.

DROZDOGAN AI

Drozdogan Assistant

Pregnancy Is Safe in Women with Early-Stage Breast Cancer and a BRCA Mutation

Ask about the article and read answers alongside published sources from our site.

Conversation and privacy information

Drozdogan Assistant answers this conversation. Authorized site administrators may review it for quality. Do not share personal information.

Replies use OpenAI infrastructure. Questions and replies are processed by that service; conversation records are stored on our site. Do not share identifying, contact or personal health information.

0 / 1000

For information only; no personal diagnosis or treatment advice.

Related articles

Explore other articles on this topic.

Stay informed

Receive new articles and scientific updates by email.

Google Analytics runs on public pages independently of this window and may use analytics cookies. Your choice here controls external services only.

Cookie policy